CN115572256A - Oct4高选择性活化剂 - Google Patents
Oct4高选择性活化剂 Download PDFInfo
- Publication number
- CN115572256A CN115572256A CN202110686581.9A CN202110686581A CN115572256A CN 115572256 A CN115572256 A CN 115572256A CN 202110686581 A CN202110686581 A CN 202110686581A CN 115572256 A CN115572256 A CN 115572256A
- Authority
- CN
- China
- Prior art keywords
- added
- ethyl acetate
- reduced pressure
- methylpyridin
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012190 activator Substances 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 239000002207 metabolite Substances 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 10
- 230000003287 optical effect Effects 0.000 claims description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 9
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 8
- 125000004450 alkenylene group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000004569 Blindness Diseases 0.000 claims description 4
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010011878 Deafness Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 238000010322 bone marrow transplantation Methods 0.000 claims description 4
- 231100000895 deafness Toxicity 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000016354 hearing loss disease Diseases 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
- 208000016361 genetic disease Diseases 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 claims description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 39
- 230000014509 gene expression Effects 0.000 abstract description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 334
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 128
- 235000019439 ethyl acetate Nutrition 0.000 description 114
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 92
- 239000000203 mixture Substances 0.000 description 83
- 238000001819 mass spectrum Methods 0.000 description 68
- 239000007791 liquid phase Substances 0.000 description 67
- 239000011541 reaction mixture Substances 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- 238000010898 silica gel chromatography Methods 0.000 description 62
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 61
- -1 benzimidazole derivative small molecules Chemical class 0.000 description 59
- 239000012044 organic layer Substances 0.000 description 57
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 56
- 229910052938 sodium sulfate Inorganic materials 0.000 description 56
- 235000011152 sodium sulphate Nutrition 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 53
- 239000002904 solvent Substances 0.000 description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 38
- 239000000243 solution Substances 0.000 description 35
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 33
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 31
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 238000004821 distillation Methods 0.000 description 26
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- LDHQXHRGRCQLFD-UHFFFAOYSA-N tert-butyl N-(5-amino-6-methylpyridin-2-yl)carbamate Chemical compound CC1=NC(NC(=O)OC(C)(C)C)=CC=C1N LDHQXHRGRCQLFD-UHFFFAOYSA-N 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 150000003384 small molecules Chemical class 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- 150000003927 aminopyridines Chemical class 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- WFRXSXUDWCVSPI-UHFFFAOYSA-N 3h-benzimidazol-5-amine Chemical compound NC1=CC=C2NC=NC2=C1 WFRXSXUDWCVSPI-UHFFFAOYSA-N 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 210000001671 embryonic stem cell Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 8
- 150000001556 benzimidazoles Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 5
- PGVBXOCZEGXNPD-UHFFFAOYSA-N CC(N=C(C=C1)N)=C1NC1CCOCC1 Chemical compound CC(N=C(C=C1)N)=C1NC1CCOCC1 PGVBXOCZEGXNPD-UHFFFAOYSA-N 0.000 description 5
- 101710150336 Protein Rex Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 4
- OFFSPAZVIVZPHU-UHFFFAOYSA-N 1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC2=C1 OFFSPAZVIVZPHU-UHFFFAOYSA-N 0.000 description 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 4
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 101150065749 Churc1 gene Proteins 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 102100038239 Protein Churchill Human genes 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(II) bromide Substances [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical compound C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 238000003032 molecular docking Methods 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- OFZCBRZVCBEWDM-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)CC2=C1 OFZCBRZVCBEWDM-UHFFFAOYSA-N 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 3
- XURBWYCGQQXTHJ-UHFFFAOYSA-N 3,4-dichlorobenzamide Chemical compound NC(=O)C1=CC=C(Cl)C(Cl)=C1 XURBWYCGQQXTHJ-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- SEOZHXRTVJPQPZ-UHFFFAOYSA-N 5-bromo-6-methylpyridin-2-amine Chemical compound CC1=NC(N)=CC=C1Br SEOZHXRTVJPQPZ-UHFFFAOYSA-N 0.000 description 3
- KIZUAJSZBUQIRP-BQYQJAHWSA-N 6-methyl-5-[(E)-2-phenylethenyl]pyridin-2-amine Chemical compound CC1=NC(N)=CC=C1\C=C\C1=CC=CC=C1 KIZUAJSZBUQIRP-BQYQJAHWSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- HPKFEUMEBGQGRH-UHFFFAOYSA-N CC(N=C(C=C1)N)=C1C(N(C)C1=CC=CC=C1)=O Chemical compound CC(N=C(C=C1)N)=C1C(N(C)C1=CC=CC=C1)=O HPKFEUMEBGQGRH-UHFFFAOYSA-N 0.000 description 3
- XCLSDVFMPBTNBC-UHFFFAOYSA-N CC(N=C(C=C1)N)=C1NC1=CC=CC=C1 Chemical compound CC(N=C(C=C1)N)=C1NC1=CC=CC=C1 XCLSDVFMPBTNBC-UHFFFAOYSA-N 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- MFSLKPGAGRMKRJ-UHFFFAOYSA-N N-(6-amino-2-methylpyridin-3-yl)-2-phenylacetamide Chemical compound CC1=NC(N)=CC=C1NC(=O)CC1=CC=CC=C1 MFSLKPGAGRMKRJ-UHFFFAOYSA-N 0.000 description 3
- ZWQFQQNSNPAHKQ-UHFFFAOYSA-N N-(6-amino-2-methylpyridin-3-yl)-3,4-dichlorobenzamide Chemical compound CC1=NC(N)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 ZWQFQQNSNPAHKQ-UHFFFAOYSA-N 0.000 description 3
- KTLDJGZRBSPKTH-UHFFFAOYSA-N N-(6-amino-2-methylpyridin-3-yl)benzamide Chemical compound CC1=NC(N)=CC=C1NC(=O)C1=CC=CC=C1 KTLDJGZRBSPKTH-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- LLBKAAHFDNMGNG-UHFFFAOYSA-N tert-butyl n-(5-bromo-6-methylpyridin-2-yl)carbamate Chemical compound CC1=NC(NC(=O)OC(C)(C)C)=CC=C1Br LLBKAAHFDNMGNG-UHFFFAOYSA-N 0.000 description 3
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 2
- DYSJMQABFPKAQM-UHFFFAOYSA-N 1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-N 0.000 description 2
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 2
- IZQAUUVBKYXMET-UHFFFAOYSA-N 2-bromoethanamine Chemical compound NCCBr IZQAUUVBKYXMET-UHFFFAOYSA-N 0.000 description 2
- DYNFCHNNOHNJFG-UHFFFAOYSA-N 2-formylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C=O DYNFCHNNOHNJFG-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- VPHHJAOJUJHJKD-UHFFFAOYSA-N 3,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(Cl)=C1 VPHHJAOJUJHJKD-UHFFFAOYSA-N 0.000 description 2
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 2
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 2
- XPAZGLFMMUODDK-UHFFFAOYSA-N 6-nitro-1h-benzimidazole Chemical compound [O-][N+](=O)C1=CC=C2N=CNC2=C1 XPAZGLFMMUODDK-UHFFFAOYSA-N 0.000 description 2
- HSBLBSFCJYEHES-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC(C1=CC=CC=C1)=O)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC(C1=CC=CC=C1)=O)=O HSBLBSFCJYEHES-UHFFFAOYSA-N 0.000 description 2
- TXKJAKJBGBJMEI-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1NCC1=CC=NC=C1)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1NCC1=CC=NC=C1)=O TXKJAKJBGBJMEI-UHFFFAOYSA-N 0.000 description 2
- MLCRWOIJBOASPT-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1NCCNS(C)(=O)=O)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1NCCNS(C)(=O)=O)=O MLCRWOIJBOASPT-UHFFFAOYSA-N 0.000 description 2
- UEMRXPQMGMSZNG-UHFFFAOYSA-N CC(C=C1)=CC=C1NC(NC1=CC=C(N)N=C1C)=O Chemical compound CC(C=C1)=CC=C1NC(NC1=CC=C(N)N=C1C)=O UEMRXPQMGMSZNG-UHFFFAOYSA-N 0.000 description 2
- DNGSTEZEDBGCNH-UHFFFAOYSA-N CC(N=C(C=C1)N)=C1NCC1=CC=NC=C1 Chemical compound CC(N=C(C=C1)N)=C1NCC1=CC=NC=C1 DNGSTEZEDBGCNH-UHFFFAOYSA-N 0.000 description 2
- YDVSXZQIMOXRDZ-UHFFFAOYSA-N CC(N=C(C=C1)N)=C1OCCC1=CC=CC=C1 Chemical compound CC(N=C(C=C1)N)=C1OCCC1=CC=CC=C1 YDVSXZQIMOXRDZ-UHFFFAOYSA-N 0.000 description 2
- RGOWCQARTSCPDO-UHFFFAOYSA-N CC1(C=CC(NC2=CC=CC=C2)=CC1)[N+]([O-])=O Chemical compound CC1(C=CC(NC2=CC=CC=C2)=CC1)[N+]([O-])=O RGOWCQARTSCPDO-UHFFFAOYSA-N 0.000 description 2
- MPSNNNAXSHKOAK-UHFFFAOYSA-N CC1=NC(N)=CCC1(C1CCC1)N Chemical compound CC1=NC(N)=CCC1(C1CCC1)N MPSNNNAXSHKOAK-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 2
- 229940106681 chloroacetic acid Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 2
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 2
- 210000002304 esc Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- OINIXPNQKAZCRL-UHFFFAOYSA-L nickel(2+);diacetate;tetrahydrate Chemical compound O.O.O.O.[Ni+2].CC([O-])=O.CC([O-])=O OINIXPNQKAZCRL-UHFFFAOYSA-L 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 2
- VNNLHYZDXIBHKZ-UHFFFAOYSA-N thiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CS1 VNNLHYZDXIBHKZ-UHFFFAOYSA-N 0.000 description 2
- DAUYIKBTMNZABP-UHFFFAOYSA-N thiophene-3-carboxamide Chemical compound NC(=O)C=1C=CSC=1 DAUYIKBTMNZABP-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 1
- PCOFIIVWHXIDGT-UHFFFAOYSA-N 3-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=CC(C#N)=C1 PCOFIIVWHXIDGT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- KRKSOBREFNTJJY-UHFFFAOYSA-N 5-hydroxybenzimidazole Chemical compound OC1=CC=C2NC=NC2=C1 KRKSOBREFNTJJY-UHFFFAOYSA-N 0.000 description 1
- BGMZTBKXOFFTBJ-UHFFFAOYSA-N 6-methyl-5-nitropyridin-2-amine Chemical compound CC1=NC(N)=CC=C1[N+]([O-])=O BGMZTBKXOFFTBJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- INRIKJMXDZECPJ-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1C(N(C)C1=CC=CC=C1)=O)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1C(N(C)C1=CC=CC=C1)=O)=O INRIKJMXDZECPJ-UHFFFAOYSA-N 0.000 description 1
- QVUYZYYYOBNCSZ-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1N(CC1=CC=CC=C11)C1=O)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1N(CC1=CC=CC=C11)C1=O)=O QVUYZYYYOBNCSZ-UHFFFAOYSA-N 0.000 description 1
- ASTUDQKNBHJENK-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC(C1=CSC=C1)=O)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC(C1=CSC=C1)=O)=O ASTUDQKNBHJENK-UHFFFAOYSA-N 0.000 description 1
- JVTIAPDAROWFMX-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC(NC1=CC(Br)=CC=C1)=O)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC(NC1=CC(Br)=CC=C1)=O)=O JVTIAPDAROWFMX-UHFFFAOYSA-N 0.000 description 1
- KCJFCLOEUKMZMH-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC(NC1=CC=C(C)C=C1)=O)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC(NC1=CC=C(C)C=C1)=O)=O KCJFCLOEUKMZMH-UHFFFAOYSA-N 0.000 description 1
- BPYPVFDPMFSCIB-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC1=CC=CC=C1)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1NC1=CC=CC=C1)=O BPYPVFDPMFSCIB-UHFFFAOYSA-N 0.000 description 1
- RHZNCYWSFALSNP-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1NCCN)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1NCCN)=O RHZNCYWSFALSNP-UHFFFAOYSA-N 0.000 description 1
- LCQCHKDYIRHFHN-UHFFFAOYSA-N CC(C)(C)OC(NC(C=C1)=NC(C)=C1NS(C1=CC=CS1)(=O)=O)=O Chemical compound CC(C)(C)OC(NC(C=C1)=NC(C)=C1NS(C1=CC=CS1)(=O)=O)=O LCQCHKDYIRHFHN-UHFFFAOYSA-N 0.000 description 1
- NLWFCCTXLZBNIN-UHFFFAOYSA-N CC1=NC(N)=CC=C1N(C(C1=CC=CC=C11)=O)C1=O Chemical compound CC1=NC(N)=CC=C1N(C(C1=CC=CC=C11)=O)C1=O NLWFCCTXLZBNIN-UHFFFAOYSA-N 0.000 description 1
- ZASFGBXXWNINQH-UHFFFAOYSA-N CC1=NC(N)=CC=C1N(CC1=CC=CC=C11)C1=O Chemical compound CC1=NC(N)=CC=C1N(CC1=CC=CC=C11)C1=O ZASFGBXXWNINQH-UHFFFAOYSA-N 0.000 description 1
- ZXCKVZTVHQQAKK-UHFFFAOYSA-N CC1=NC(N)=CC=C1NC(C(C1)OC2=C1C=CC=C2)=O Chemical compound CC1=NC(N)=CC=C1NC(C(C1)OC2=C1C=CC=C2)=O ZXCKVZTVHQQAKK-UHFFFAOYSA-N 0.000 description 1
- JHLOSSFYAQYXCQ-UHFFFAOYSA-N CC1=NC(N)=CC=C1NC(C1=CC(C=CC=C2)=C2S1)=O Chemical compound CC1=NC(N)=CC=C1NC(C1=CC(C=CC=C2)=C2S1)=O JHLOSSFYAQYXCQ-UHFFFAOYSA-N 0.000 description 1
- KWIQUKIYKUTHLD-UHFFFAOYSA-N CC1=NC(N)=CC=C1NC(C1=CSC=C1)=O Chemical compound CC1=NC(N)=CC=C1NC(C1=CSC=C1)=O KWIQUKIYKUTHLD-UHFFFAOYSA-N 0.000 description 1
- STMYAXDTYDXPDY-UHFFFAOYSA-N CC1=NC(N)=CC=C1NCCNS(C)(=O)=O Chemical compound CC1=NC(N)=CC=C1NCCNS(C)(=O)=O STMYAXDTYDXPDY-UHFFFAOYSA-N 0.000 description 1
- BQPPPSVBRCCYSA-UHFFFAOYSA-N CC1=NC(N)=CC=C1NS(C1=CC=CS1)(=O)=O Chemical compound CC1=NC(N)=CC=C1NS(C1=CC=CS1)(=O)=O BQPPPSVBRCCYSA-UHFFFAOYSA-N 0.000 description 1
- GSHHDKDFVWCKNM-UHFFFAOYSA-N CC1=NC(N)=CC=C1OCC1=CC=CC(C#N)=C1 Chemical compound CC1=NC(N)=CC=C1OCC1=CC=CC(C#N)=C1 GSHHDKDFVWCKNM-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101001013403 Homo sapiens Meiosis initiator protein Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 102100029699 Meiosis initiator protein Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000042835 POU transcription factor family Human genes 0.000 description 1
- 108091082602 POU transcription factor family Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008668 cellular reprogramming Effects 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- WIVXEZIMDUGYRW-UHFFFAOYSA-L copper(i) sulfate Chemical compound [Cu+].[Cu+].[O-]S([O-])(=O)=O WIVXEZIMDUGYRW-UHFFFAOYSA-L 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- DUYBICGEHMLOIU-UHFFFAOYSA-N lithium;2-phenylethanolate Chemical compound [Li+].[O-]CCC1=CC=CC=C1 DUYBICGEHMLOIU-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- JIKUXBYRTXDNIY-UHFFFAOYSA-N n-methyl-n-phenylformamide Chemical compound O=CN(C)C1=CC=CC=C1 JIKUXBYRTXDNIY-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VSNSCGBZXFVXBR-UHFFFAOYSA-N tert-butyl N-(6-methyl-5-nitropyridin-2-yl)carbamate Chemical compound Cc1nc(NC(=O)OC(C)(C)C)ccc1[N+]([O-])=O VSNSCGBZXFVXBR-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
技术领域
本发明涉及医药领域,具体涉及OCT4高选择性活化剂,其药物组合物及制备方法,及其在调控Oct4及其关联基因的调控中的应用。
背景技术
再生医学是指利用多种新型技术学科来重建老化或功能损失的组织和器官,并通过多种医学手段来进行相关疾病治疗的新兴科学。再生医学的重要研究方向为正常组织特征与功能的机理,创伤后修复的生物学基础,以及组织器官的再生机制及多种干细胞分化机理,从而最终获得有效的生物治疗方法。其中,胚胎干细胞(Embryonic stem cell,ESCs,简称ES、 EK或ESC细胞)是早期再生医学研究中最受人瞩目的细胞类型。但是这一细胞的获得和使用均具有较大的伦理争议,因为进行胚胎干细胞研究就必须破坏胚胎,而胚胎是人尚未成形时在子宫的生命形式。这一伦理争议大大阻碍了再生医学的推进和应用。
2006年,山中伸弥的团队发明了一种由OCT4,SOX2,KLF4和c-Myc四种转录因子构成的“鸡尾酒”法,能够成功将终端分化的皮肤成纤维细胞重编程成为具有分化多能性的干细胞,这种干细胞被称为诱导多能干细胞(induced pluripotent cells)(Takahashi K,etal.,Cell, 2006,126(4)pp.663-676;Takahashi K and Yamanaka S,Cell,2007,131(5)pp.861-872)。这些干细胞具有和胚胎干细胞(embryonic stem cells)类似的分化潜能,能够形成人体发育最基本的三个胚层:外胚层,中胚层及内胚层,并最终形成多种成体细胞。这一发明突破了在医学上使用人胚胎干细胞的伦理限制,大大拓展了干细胞技术在临床医学上的应用潜力。
在诱导多能干细胞及胚胎干细胞的研究中,Oct4已被证明是重编程和诱导细胞可塑性的主要调节基因(Malik,V et al.,Nat.Commun.2019,10,3477)。Oct4基因编码的蛋白质在胚胎发育和干细胞多能性中起关键作用,选择性剪接导致多种转录物变体。Oct4编码的蛋白质属于转录因子的POU结构域家族,位于Chromosome 17:35,825,200-35,829,401。POU 转录因子家族的标志性特征是POU域,它由两个结构独立的亚域组成:一个由高度保守75 个氨基酸构成的POU特异(POU)区和一个60个氨基酸的羧基末端同源域(POUh)。Oct4 的表达在转录水平受到Oct4基因上游的顺式作用元件和染色质结构甲基化的调控(KlemmJD,et al.,Cell,1994,77:21-32;Brehm A,et al.,Mol Cell Biol 1997;17:154-62)。Yeom 等人通过分析来自Oct4基因组基因座的18Kb片段控制下LacZ报告基因的表达,确定了两个元素,他们将其命名为可能需要调节的近端增强子(PE)和远端增强子(DE),他们在这两个增强子中确定了转录因子的精确结合位点(Yeom Y,et al.Integrated AnnIndexes 1996; 122:881-94)。POU域转录因子与特定的八聚体DNA结合并调节细胞类型特异性的分化途径。其中,在iPSC形成过程中,含有POU结构域的Oct4和含有HMG结构域的Sox2是维持多能细胞多能性至关重要的转录因子(Nichols,J.,et al.,Cell,1998,95,379–391;Avilion,A., et al.,2003,Genes Dev.17,126–140),它们在多能细胞中的至少部分功能是通过两者之间的协同相互作用来驱动靶基因的转录(Tomioka,M.,et al.NucleicAcids Res.2002;30,3202– 3213)。这些发现表明发育上的转换可以通过Oct4来控制。而目前广泛使用的重编程方法多通过病毒或者其它类型的载体来过表达Oct4(Takahashi K,etal.,Cell,2006,126(4): 663-676;Takahashi K and Yamanaka S,Cell,2007,131(5):861-872);Yu J,et al. Science.2007;318:1917–1920)。此类方法在诱导多能干细胞(iPSC)的临床使用上存在潜在的临床风险,例如病毒载体的使用带来的致瘤性隐患;此外,载体的复杂GMP生产工艺也带来了诱导多能干细胞临床监管复杂性,进一步的,此类产品会因为载体的使用带来成本的高昂。
基于上述原因,本发明设计并使用苯并咪唑衍生物及氨基吡啶衍生物,通过Oct4启动子的化学调节,实现对其下游基因的表达调控。从而避免了使用病毒或者其它载体对Oct4 的调控,进一步实现安全简便的化学小分子启动生物学表达功能。
发明内容
本发明涉及式(I)结构的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、酯、光学异构体或前药,包含式(I)结构的化合物的药物组合物及其作为OCT4 高选择性活化剂用于细胞的重编程。
本发明提供了一种式(I)结构的化合物:
其中:
m1和m2分别为0或1;
A2是C1-C6亚烷基、C2-C6亚烯基、-O(CH2)q-、-NR1-、-SO2-、-(CH2)VNHS(O)2-或键,其中,q为1或2或3或4,V为0或1或2,R1选自H或C1-C4烷基;
A3是C1-C6烷基;C2-C6烯基;C4-C6环烷基,其中一个碳原子可被N、O、S杂原子取代;Z和Z1分别为N或CR2,R2选自H、卤素、C1-C4 烷基或氰基;Z3为N、O、S或C=O,当Z4和Z5之间的键为单键时, Z4为N或CH,Z5为CH2或C=O,当Z4和Z5之间的键为双键时,Z4为C,Z5为CH;
及其药物上可接受的盐、溶剂化物、活性代谢物、多晶型物、酯、光学异构体、前药或其组合。
在某些实施方案中,本发明公开的化合物具有式(II)或式(III):
其中:
A2是-CH2-、-CH=CH-、-C(CH3)=CH-、-O(CH2)-、-O(CH2)2-、-NH-、-N(CH3)-、-NHS(O)2-、 -(CH2)2NHS(O)2-或不存在。
在一些实施例中:m1是0,m2是1;
A2是-N(CH3)-;
在一些实施例中:m1是1,m2是0;
A2是-CH2-、-SO2-、-(CH2)2NHS(O)2-或键;
在一些实施例中:m1是1,m2是1;
A2是-CH2-、-NH-、-C(CH3)=CH-或键;
在一些实施例中:m1是0,m2是0;
A2是-CH2-、-CH=CH-、-O(CH2)-、-O(CH2)2-或键;
在一些实施例中,化合物为:
本发明涉及药物组合物,药物组合物包含上述中任意一项的化合物及其药物上可接受的盐、溶剂化物、活性代谢物、多晶型物、酯、光学异构体、前药或其组合,以及至少一种药学上可接受的载体或赋形剂。
本发明涉及上述任意一项的所述的化合物和/或其药物上可接受的盐、溶剂化物、活性代谢物、多晶型物、酯、光学异构体、前药或其组合在制备诱导多能干细胞的OCT4高选择性活化剂的药物中的用途。
本发明涉及在制备诱导多能干细胞的OCT4高选择性活化剂的药物中的用途,其OCT4 高选择性活化剂诱导多能干细胞治疗的疾病包括癌症、心脏病、中风、糖尿病、肥胖、阿尔茨海默氏病、帕金森氏病、肌萎缩侧索硬化、心肌梗塞、肌营养不良、CMT-1A、脊髓损伤、外伤性脑损伤、缺牙、伤口愈合、骨髓移植、骨关节炎、类风湿性关节炎、脱发、失明、耳聋、克罗恩氏病和遗传疾病及其他相似疾病。
本发明涉及一种在患有疾病的受试者中获得诱导多能干细胞的方法,该方法包括向该受试者施用治疗有效量的上述任一项的化合物和/或其药物上可接受的盐、溶剂化物、活性代谢物、多晶型物、酯、光学异构体、前药或其组合。
所述方法中,患有疾病的受试者是指患有癌症、心脏病、中风、糖尿病、肥胖、阿尔茨海默氏病、帕金森氏病、肌萎缩侧索硬化、心肌梗塞、肌营养不良、CMT-1A、脊髓损伤、外伤性脑损伤、缺牙、伤口愈合、骨髓移植、骨关节炎、类风湿性关节炎、脱发、失明、耳聋、克罗恩氏病和遗传疾病及其他相似疾病的人类。
本发明涉及一种活化OCT4功能的方法,其包括使上述任一项的化合物和/或其药物上可接受的盐、溶剂化物、活性代谢物、多晶型物、酯、光学异构体、前药或其组合与OCT4靶标蛋白接触。
附图说明
图1显示的是氨基吡啶衍生物小分子对OCT4的基础表达及其下游基因Nanog的表达的结果(其中CK为对照组);
图2显示的是苯并咪唑衍生物小分子对OCT4的基础表达及其下游基因Nanog的表达的结果(其中CK为对照组);
图3显示的是氨基吡啶衍生物及苯并咪唑衍生物化学小分子促进间充质细胞表达Rex l 基因,形成多能干细胞克隆样细胞团的免疫荧光染色图片(其中CK为对照组)
具体实施方式
在本发明中,以下定义是可适用的:
本文的术语“烷基”是指含有1-12个碳原子的直链或支链饱和烃。(C1-C6)烷基的实例包括但不限于甲基、乙基、丙基、丁基、戊基、己基、异丙基、异丁基、仲丁基、叔丁基、异戊基、新戊基和异己基。
术语“烯基”是指含有2-12个碳原子的直链或支链不饱和烃,在链中含有至少一个C=C 双键。烯基的实例包括乙烯基、丙烯基、正丁烯基、异丁烯基、戊烯基或己烯基。
术语“亚烷基”:是指二价烷基。单价烷基中的任一个可通过从烷基中夺取第二氢原子而为亚烷基。如本文所定义,亚烷基还可以是C1-C6亚烷基。亚烷基可进一步是C1-C4亚烷基。典型的亚烷基包括但不限于:-CH2-、-CH(CH3)-、-C(CH3)2-、-CH2CH2-、-CH2CH(CH3)-、-CH2C(CH3)2-、-CH2CH2CH2-、-CH2CH2CH2CH2-等。
术语“亚烯基”:是指二价烯基。单价烯基中的任一个可通过从烯基中夺取第二氢原子而为亚烯基。如本文所定义,亚烯基可进一步是C2-C6亚烯基。典型的亚烯基包括但不限于: -CH=CH-、-CH=C(CH3)-、-CH=CHCH2-、-CH=CHCH2CH2-、-CH=CHCH2CH2CH2-、 -CH=CHCH2CH2CH2CH2-等。
术语“环烷基”是指含有3-18个碳原子的单环饱和碳环。环烷基可进一步是C4-C6环烷基。环烷基的实例包括但不限于环丙基、环丁基、环戊基、环己基、环庚基、环辛基等。
术语“卤素”是指氟、氯、溴或碘。
术语“氰基”是指具有通过三键(即C≡N)与氮原子连接的碳原子的取代基。
本文所用的术语“取代”,指的是指定的原子或基团上的任意一个或多个氢原子被选自指定的范围中的基团替换,条件是不超过所述指定原子的正常化合价。
本文所述的化合物包括但不限于:它们的光学异构体、外消旋体以及其他混合物。在这些情况下,单个对映异构体或非对映异构体,即光学活性构型,可以通过不对称合成或通过拆分外消旋体或非对映异构体混合物来获得。对于外消旋体或非对映异构体混合物的拆分,可通过常规的方法来完成,例如在拆分剂存在下结晶或使用例如手性高压液相色谱(HPLC) 柱的色谱法完成。此外,这些化合物包括R-和S-构型的具有手性中心的化合物。这些化合物还包括晶型,包括多晶型物和包合物。类似地,术语“盐”也包括了所述化合物的盐的所有异构体、外消旋体、其他混合物、R-和S-构型、互变异构体和晶型。
“药物上可接受的盐”,指的是无毒的、生物学上可耐受的或其他方面在生物学上适合于给予治疗个体的式(I)、式(II)或式(III)代表的化合物的游离酸或碱的盐。一般参见: S.M.Berge,et al.,“Pharmaceutical Salts”,J.Pharm.Sci.,1977,66:1-19,以及Handbook ofPharmaceutical Salts,Properties,Selection,and Use,Stahl andWermuth,Eds.,Wiley-VCH and VHCA,Zurich,2002。优选地药学上可接受的盐是指那些药理学上有效的并且适合于接触病人组织而无异常毒性、刺激或过敏反应的盐。式(I)、式(II)或式(III)的化合物可以具有足够的酸性基团、足够的碱性基团或兼具这两种类型的功能基团,并相应地与一些无机或有机碱、及无机和有机酸反应,形成一种药学上可接受的盐。药学上可接受的盐的实例包括硫酸盐、焦硫酸盐、硫酸氢盐、亚硫酸盐、亚硫酸氢盐、磷酸盐、单氢磷酸盐、二氢磷酸盐、偏磷酸盐、焦磷酸盐、盐酸盐、氢溴酸盐、氢碘酸盐、醋酸盐、丙酸盐、癸酸盐、辛酸盐、丙烯酸盐、甲酸盐、异丁酸盐、己酸盐、庚酸盐、丙炔酸盐、草酸盐、丙二酸盐、琥珀酸盐、辛二酸盐、癸二酸盐、富马酸盐、马来酸盐、丁炔-1,4-二酸盐、己炔-1,6-二酸盐、苯甲酸盐、氯代苯甲酸盐、甲基苯甲酸盐、二硝基苯甲酸盐、羟基苯甲酸盐、甲氧基苯甲酸盐、邻苯二甲酸盐、磺酸盐、二甲苯磺酸盐、苯乙酸盐、苯丙酸盐、苯丁酸盐、柠檬酸盐、乳酸盐、γ-羟基丁酸盐、羟乙酸盐、酒石酸盐、甲烷磺酸盐、丙磺酸盐、萘-1-磺酸盐、萘-2-磺酸盐和扁桃酸盐。
“溶剂化物”例如“水合物”是通过溶剂与化合物的相互作用形成的。术语“化合物”包括化合物的溶剂化物,包括水合物。同样地,“盐”包括盐的溶剂化物,例如水合物。合适的溶剂化物是药学上可接受的溶剂化物,例如水合物,包括一水合物和半水合物。
“前药”可指指定化合物的前体,它在对受治疗者施用后,在体内经化学或生理学过程 (如溶剂分解、酶分解)或在生理条件下(如在生理pH条件下将前药转化为式(I)化合物),得到该化合物。“药学上可接受的前药”是无毒的、生物学上耐受的或其它方面在生物学上适宜对受治疗者施用的前药。示例性的选择和制备合适的前药衍生物的程序在例如H.Bundgaard编著的“Design of Prodrugs”,Elsevier,1985中有描述。
“活性代谢物”指式(I)、式(II)或式(III)化合物或其盐在体内代谢的药学活性产物。可用本领域已知的或可获得的常规技术测定化合物的前药和活性代谢物。例如见Bertolini 等,J.Med.Chem.1997,40,2011-2016;Shan等,J.Pharm.Sci.1997,86(7),765-767;Bagshawe, Drug Dev.Res.1995,34,220-230;Bodor,Adv.Drug Res.1984,13,224-331;Bundgaard, Design of Prodrugs(ElsevierPress,1985);及Larsen,Design andApplication of Prodrugs,Drug Design andDevelopment(Krogsgaard-Larsen et al.,eds.,Harwood Academic Publishers,1991)
“治疗有效量”是指当施用于哺乳动物(优选人)时足以实现哺乳动物(优选人)的疾病或病症的治疗(如以下定义)的本文公开的化合物的量。构成“治疗有效量”的公开的化合物的量将随着化合物、病症及其严重性和被治疗的哺乳动物的年龄而变化,但是可以由本领域普通技术人员根据他自己的知识和本文公开内容来常规确定。
术语“治疗”,指的是给予个体施用本文所述的至少一种化合物和/或至少一种其药学上可接受的盐,以减缓(减少)不希望发生的生理变化或疾病,例如炎症或癌症的发展或扩散。本发明的目的,有益的或期望的临床结果包括但不限于:减轻症状、减少疾病的严重程度、稳定(即,不恶化)疾病的状态、延迟或延缓疾病进展、改善或缓和病情、以及缓解(无论是部分还是全部)无论是检测到的还是检测不到的疾病。与那些不接受治疗的预计生存期相比,“治疗”也意味着可以延长生存期。需要治疗的个体包括具有这些疾病的症状或患有这些疾病的个体。
药物组合物
本发明提供了药物组合物,其包含一种或多种文中所述的化合物或其药学上可接受的盐或酯作为活性成分,以及一种或多种药学上可接受的赋形剂、载体,包括惰性固体稀释剂和填料、稀释剂,包括无菌水溶液和多种有机溶剂、渗透促进剂、增溶剂和助剂。该药物组合物可以单独给药或与其他治疗剂一起给药。此类组合物以药学领域公知的方式制备。
该药物组合物可以单剂量或多剂量,通过任一具有类似用途的药剂的可接受的方式给药,例如在此引入作为参考的那些专利和专利申请中所描述的,包括直肠、口含、鼻内和透皮途径、通过动脉内注射、静脉、腹膜内、肠胃外、肌内、皮下、口服、局部、作为吸入剂,或通过植入或包衣设备如支架,例如或者动脉插入柱状聚合物。
本发明还提供试剂盒,其包括包含本发明化合物或其药学上可接受的盐的药物组合物,和至少一种药学上可接受的载体。
“药学上可接受的载体或赋形剂”是指无毒的、生物学上可耐受的并且其他在生物学上适用于给予个体的物质,例如惰性物质,其被加入到药理学组合物中或者用作媒介、载体或稀释以方便活性成分的给药并与之相容。赋形剂的实例包括碳酸钙、磷酸钙、各种类型的糖或淀粉、纤维素衍生物、明胶、植物油和聚乙二醇。
化合物及其组合物的用途
本发明提供了化合物及其组合物的用途,其主要作为OCT4高选择性活化剂,用于活化 OCT4功能,通过对Oct4启动子的化学调节,实现对其下游基因的表达调控,进而在患有疾病的受试者中诱导多能干细胞,实现治疗疾病的目的,所述疾病包括癌症、心脏病、中风、糖尿病、肥胖、阿尔茨海默氏病、帕金森氏病、肌萎缩侧索硬化、心肌梗塞、肌营养不良、CMT-1A、脊髓损伤、外伤性脑损伤、缺牙、伤口愈合、骨髓移植、骨关节炎、类风湿性关节炎、脱发、失明、耳聋、克罗恩氏病和遗传疾病及其他相似疾病。
在以下实施例和本文其他地方使用到的缩写列表:
Atm:气氛;Boc:叔丁氧基羰基;(Boc)2O:二叔丁基二碳酸酐;CH2Cl2:二氯甲烷;Cs2CO3:碳酸铯;Cu(I)Br:溴化铜;Cu2SO4:硫酸亚铜;DCM:二氯甲烷;DMAC:N,N- 二甲基乙酰胺;DMF:N,N-二甲基甲酰胺;DIEA:N,N-二异丙基乙胺;DIOX:1,4-二氧六环;dioxane:二氧六环;EA:乙酸;Et3N:三乙胺;ETOH:乙醇;EtOAc:乙酸乙酯;FA:甲酸;g:克;h:小时;H2:氢气;HATU:2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯;HBr:氢溴酸;(Hbim)BF4:1-丁基咪唑四氟硼酸盐;H2O:水;HAc:乙酸;H2O2:过氧化氢;H2SO4:发烟硫酸;KCN:氰化钾;K2CO3:碳酸钾;Li:锂;MCA:氯乙酸; MeCN:乙腈;MeOH:甲醇;mg:毫克;ml:毫升;mmol:毫摩尔;mol:摩尔;m/z:质荷比;N2:氮气;NaBH3CN:氰基硼氢化钠;NaNO2:亚硝酸钠;NaOH:氢氧化钠; NaOMe:甲醇钠;Na2SO4:硫酸钠;Ni(OAc)2 4H2O:四水合二乙酸镍;Pd-C:钯碳;PH:酸碱度;TBN:亚硝基叔丁酯;TEA:三乙醇胺;THF:四氢呋喃;TLC:薄层色谱;Xylene:二甲苯。
以下配合图式及本发明的实施例,进一步阐述本发明为达成预定发明目的所采取的技术手段。下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的原料、试剂材料等,如无特殊说明,均为市售购买产品。
通用合成
本申请中所给的描述的通用合成路线可以通过用具有类似结构的其他原料替换起始原料,从而相应地得到不同的产物而进行变化。下面的合成路线描述给出了起始原料可如何变化得到相应产物的多个实例。
通用方法A-1-n
通用方法A-2-n
通用方法A-4-n
通用方法A-6-n
通用方法B-1-n
其中R的定义同通用方法A-1-n中R的定义。
通用方法B-3-n
其中R的定义同通用方法A-2-n中R的定义。
通用方法B-4-n
其中R的定义同通用方法A-4-n中R的定义。
通用方法B-6-n
其中R的定义同通用方法A-6-n中R的定义。
中间体合成
中间体Ⅰ-3:(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯
合成路线:
步骤1:将6-甲基-5-硝基吡啶-2-胺I-1(15.3g,0.1mol)与二叔丁基二碳酸酐(26.2g,0.12mol)与K2CO3(69g,0.5mol)混合,添加四氢呋喃(200ml),室温搅拌3小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用水洗涤,用硫酸钠干燥,减压蒸馏除去溶剂,得到(6-甲基-5-硝基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-2(23.3g,92%)液相质谱m/z=254.1[M+H]+
步骤2:将上述(6-甲基-5-硝基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-2(12.7g,0.05mol)与 10%Pd-C(1g)和MeOH(100mL)在氢气氛(1atm)下在室温下搅拌2h。过滤混合物,减压蒸馏除去溶剂,得到中间体(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-3(11g,98%) 液相质谱m/z=224.1[M+H]+
中间体II-3:1H-苯并[d]咪唑-6-醇
合成路线:
步骤1:中间体1H-苯并[d]咪唑-6-重氮II-2
1H-苯并[d]咪唑-6-胺(67mg,0.5mmol)中添加水(2ml)和20%的H2SO4水溶液(1ml)。在冰冷却下向混合物中添加亚硝酸钠水溶液(42mg,0.6mmol)溶液(0.5ml)和乙腈(2ml),并将混合物搅拌30分钟。向获得的反应混合物中添加室温下存于20%HBr水溶液(0.5ml)中的Cu2SO4(67mg,0.3mmol)溶液,并且在80℃下将混合物搅拌30分钟。向反应混合物中加入乙酸乙酯和水。分离有机层,用盐水冲洗,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(氯仿:甲醇=50:1)纯化得到IⅠ-2的硫酸氢盐(85mg,70%),液相质谱 m/z=145.1[m]+。
步骤2:中间体1H-苯并[d]咪唑-6-醇II-3
将1H-苯并[d]咪唑-6-重氮的硫酸氢盐(48mg,0.2mmol)的水溶液(1ml),滴加到100℃的40%硫酸水溶液(5ml)中,并将混合物搅拌10分钟。向获得的反应混合物中添加NaOH 至PH约为3,向反应混合物中加入乙酸乙酯,分离有机层,用盐水冲洗,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(氯仿:甲醇=50:1)纯化得到IⅠ-3(19mg,69%),液相质谱 m/z=134.1[m+H]+。
实施例1:3-(((6-氨基-2-甲基吡啶-3-基)氧基)甲基)苯甲腈A-1-1
步骤1:(3-氰基苯基)甲醇锂Ⅰ-5-1
将(3-氰基苯基)甲醇(20mg,0.15mol)与金属锂(12mg,1.73mmol)混合,添加四氢呋喃(3mL)20℃下搅拌3h.过滤混合物,减压蒸馏除去溶剂,得到(3-氰基苯基)甲醇锂Ⅰ-5-1(20mg,96%)。
步骤2:3-(((6-氨基-2-甲基吡啶-3-基)氧基)甲基)苯甲腈
将(3-氰基苯基)甲醇锂Ⅰ-5-1(20mg,0.14mol)与5-溴-6-甲基吡啶-2-胺Ⅰ-6(32mg, 0.17mol)混合,加入溴化亚铜(28mg,0.2mol),甲醇(1mL),N,N二甲基甲酰胺(3mL),油浴加热110℃下搅拌1h。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:甲醇=40:1)纯化得到3-(((6-氨基-2-甲基吡啶-3-基)氧基)甲基)苯甲腈A-1-1(26g,78%)液相质谱m/z=240.1[M+H]+
实施例2:6-甲基-5-苯乙氧基吡啶-2-胺A-1-2
步骤1:2-苯基乙醇锂Ⅰ-5-2
将2-苯基乙醇(18mg,0.15mol)与金属锂(12mg,1.73mmol)混合,添加四氢呋喃(3mL)20℃下搅拌3h.过滤混合物,减压蒸馏除去溶剂,得到2-苯基乙醇锂Ⅰ-5-2(18mg,94%)。
步骤2:6-甲基-5-苯乙氧基吡啶-2-胺A-1-2
将2-苯基乙醇锂Ⅰ-5-2(18mg,0.14mol)与5-溴-6-甲基吡啶-2-胺(32mg,0.17mol)混合,加入溴化亚铜(28mg,0.2mol),甲醇(1mL),N,N二甲基甲酰胺(3mL),油浴加热110℃下搅拌1h。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:甲醇=40:1)纯化得到6-甲基-5-苯乙氧基吡啶-2- 胺(22g,69%)液相质谱m/z=228.1[M+H]+
实施例3:N-(6-氨基-2-甲基吡啶-3-基)噻吩-3-甲酰胺A-2-1
步骤1:(6-甲基-5-(噻吩-3-甲酰胺基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-1
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与噻吩-2-羧酸(15mg, 0.12mmol)与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到(6-甲基-5-(噻吩-3-甲酰胺基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-1(16mg,48%)液相质谱m/z=334.1[M+H]+
步骤2:N-(6-氨基-2-甲基吡啶-3-基)噻吩-3-甲酰胺
向(6-甲基-5-(噻吩-3-甲酰胺基)吡啶-2-基)氨基甲酸叔丁酯(16mg,0.05mmol)中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到N-(6-氨基-2-甲基吡啶-3-基)噻吩-3-甲酰胺A-2-1(11mg,94%)液相质谱m/z=234.0[M+H]+
实施例4:(E)N-(6-氨基-2-甲基吡啶-3-基)-2-甲基-2-烯酰胺A-2-2
步骤1:(E)-(6-甲基-5-(2-甲基-2-烯酰胺基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-2
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与(E)-2-甲基-2-烯酸 (12mg,0.12mmol)与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol) 混合,添加N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到(E)-(6-甲基-5-(2-甲基-2-烯酰胺基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-2(19mg,62%)液相质谱m/z=306.1[M+H]+
步骤2:(E)N-(6-氨基-2-甲基吡啶-3-基)-2-甲基-2-烯酰胺
向(E)-(6-甲基-5-(2-甲基-2-烯酰胺基)吡啶-2-基)氨基甲酸叔丁酯(19mg,0.06mmol)中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到(E)N-(6-氨基-2-甲基吡啶-3-基)-2-甲基-2-烯酰胺A-2-2(12mg,97%) 液相质谱m/z=206.1[M+H]+
实施例5:N-(6-氨基-2-甲基吡啶-3-基)-2,3-二氢苯并呋喃-2-甲酰胺A-2-3
步骤1:(5-(2,3-二氢苯并呋喃-2-甲酰胺)-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-3
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与苯并呋喃-2-羧酸(19mg, 0.12mmol)与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到(5-(2,3-二氢苯并呋喃-2-甲酰胺)-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-3(20mg,55%)液相质谱m/z=370.2[M+H]+
步骤2:N-(6-氨基-2-甲基吡啶-3-基)-2,3-二氢苯并呋喃-2-甲酰胺
向(5-(2,3-二氢苯并呋喃-2-甲酰胺)-6-甲基吡啶-2-基)氨基甲酸叔丁酯(20mg,0.055mmol) 中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3: 7),减压蒸馏除去溶剂,得到N-(6-氨基-2-甲基吡啶-3-基)-2,3-二氢苯并呋喃-2-甲酰胺A-2-3 (11mg,74%)液相质谱m/z=270.1[M+H]+
实施例6:N-(6-氨基-2-甲基吡啶-3-基)-3,4-二氯苯甲酰胺A-2-4
步骤1:(5-(3,4-二氯苯甲酰胺)-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-4
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与3,4-二氯苯甲酸(23mg,0.12mmol)与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到(5-(3,4-二氯苯甲酰胺)-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-4(20mg,51%)液相质谱m/z=396.1[M+H]+
步骤2:N-(6-氨基-2-甲基吡啶-3-基)-3,4-二氯苯甲酰胺A-2-4
向(5-(3,4-二氯苯甲酰胺)-6-甲基吡啶-2-基)氨基甲酸叔丁酯(20mg,0.05mmol)中加入 HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到N-(6-氨基-2-甲基吡啶-3-基)-3,4-二氯苯甲酰胺A-2-4(14mg,86%)液相质谱m/z=295.0[M+H]+
实施例7:N-(6-氨基-2-甲基吡啶-3-基)苯并噻吩-2-甲酰胺A-2-5
步骤1:(5-(苯并噻吩-2-甲酰胺)-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-5
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与苯并噻吩-2-羧酸(21mg, 0.12mmol)与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到(5-(苯并噻吩-2-甲酰胺)-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-5(22mg,57%)液相质谱m/z=384.1[M+H]
步骤2:N-(6-氨基-2-甲基吡啶-3-基)苯并噻吩-2-甲酰胺
向(5-(苯并噻吩-2-甲酰胺)-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.057mmol)中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到N-(6-氨基-2-甲基吡啶-3-基)苯并噻吩-2-甲酰胺A-2-5(11mg,68%) 液相质谱m/z=284.1[M+H]+
实施例8:N-(6-氨基-2-甲基吡啶-3-基)-2-苯乙酰胺A-2-6
步骤1:(6-甲基-5-(2-苯基乙酰胺)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-6
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与2-苯乙酸(16mg, 0.12mmol)与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到(6-甲基-5-(2-苯基乙酰胺)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-6 (18mg,53%)液相质谱m/z=342.2[M+H]+
步骤2:N-(6-氨基-2-甲基吡啶-3-基)-2-苯乙酰胺:
向(6-甲基-5-(2-苯基乙酰胺)吡啶-2-基)氨基甲酸叔丁酯(18mg,0.05mmol)中加入HCl 的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到N-(6-氨基-2-甲基吡啶-3-基)-2-苯乙酰胺A-2-6(12mg,94%)液相质谱m/z=242.1[M+H]+
实施例9:N-(6-氨基-2-甲基吡啶-3-基)苯甲酰胺A-2-7
步骤1:中间体(5-苯甲酰胺基-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-7
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与2-苯甲酸(15mg,0.12mmol)与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到(5-苯甲酰胺基-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-8-7 (15mg,46%)液相质谱m/z=328.2[M+H]+
步骤2:N-(6-氨基-2-甲基吡啶-3-基)苯甲酰胺
向(5-苯甲酰胺基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(15mg,0.046mmol)中加入HCl 的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到N-(6-氨基-2-甲基吡啶-3-基)苯甲酰胺A-2-7(10mg,96%)液相质谱 m/z=227.1[M+H]+
实施例10:2-(6-氨基-2-甲基吡啶-3-基)异吲哚-1-酮A-3
其合成路线为:
步骤1:(6-甲基-5-(1-氧异吲哚-2-基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-10
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与2-甲酰基苯甲酸(18mg, 0.12mmol)混合,添加甲酸(0.2ml),三乙胺(1ml),乙醇(1ml),将混合物加热至80℃搅拌60分钟。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:乙酸乙酯=20:1)纯化得到(6-甲基-5-(1-氧异吲哚-2-基)吡啶 -2-基)氨基甲酸叔丁酯Ⅰ-10(20mg,59%)液相质谱m/z=340.4[M+H]+
步骤2:2-(6-氨基-2-甲基吡啶-3-基)异吲哚-1-酮
向(6-甲基-5-(1-氧异吲哚-2-基)吡啶-2-基)氨基甲酸叔丁酯(20mg,0.059mmol)中加入 HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到2-(6-氨基-2-甲基吡啶-3-基)异吲哚-1-酮A-3(12mg,85%)液相质谱m/z=240.1[M+H]+
实施例11:1-(6-氨基-2-甲基吡啶-3-基)-3-(对甲苯基)脲A-4-1
步骤1:对硝基苯基对甲苯氨基碳酸酯I-13-1
将对甲苯胺(21mg,0.2mmol)与4-硝基苯基羰酰氯(48mg,0.24mmol)混合,添加三乙醇胺(0.2ml),二氯甲烷(1ml),四氢呋喃(2ml)室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:己烷=5:1)纯化得到对硝基苯基对甲苯氨基碳酸酯I-13-1(42mg,77%)液相质谱m/z= 273.1[M+H]+
步骤2:(6-甲基-5-(3-(对甲苯基)脲基)吡啶-2-基)氨基甲酸叔丁酯I-14-1
将对硝基苯基对甲苯氨基甲酸酯(27mg,0.1mmol)与(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(26mg,0.12mmol)与K2CO3(0.2g,1.45mmol)混合,添加乙腈(3ml)加热至 40℃搅拌4小时。反应完成后(通过TLC监测),将反应混合物分离在真空中浓缩。这样得到的粗反应混合物用二氯甲烷洗涤,然后用EtOAc洗涤,最后用MeOH(各1mL)洗涤。最后,使用EtOAc(在温暖条件下)对反应产物进行重结晶以得到纯形式的(6-甲基-5-(3-(对甲苯基)脲基)吡啶-2-基)氨基甲酸叔丁酯I-14-1(28mg,80%)液相质谱m/z=357.2[M+H]+
步骤3:1-(6-氨基-2-甲基吡啶-3-基)-3-(对甲苯基)脲:
向(6-甲基-5-(3-(对甲苯基)脲基)吡啶-2-基)氨基甲酸叔丁酯(28mg,0.08mmol)中加入 HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到1-(6-氨基-2-甲基吡啶-3-基)-3-(对甲苯基)脲A-4-1(16mg,78%) 液相质谱m/z=257.1[M+H]+
实施例12:1-(6-氨基-2-甲基吡啶-3-基)-3-(对甲苯基)脲A-4-2
步骤1:4-硝基苯基(3-溴苯基)氨基碳酸酯I-13-2
将3-溴苯胺(34mg,0.2mmol)与4-硝基苯基羰酰氯(48mg,0.24mmol)混合,添加三乙醇胺(0.2ml),二氯甲烷(1ml),四氢呋喃(2ml)室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:己烷=5:1)纯化得到4-硝基苯基(3-溴苯基)氨基碳酸酯I-13-2(46mg,68%)液相质谱 m/z=338.1[M+H]+
步骤2:(5-(3-(3-溴苯基)脲基)-6-甲基吡啶-2-基)氨基甲酸叔丁酯I-14-2
将4-硝基苯基(3-溴苯基)氨基碳酸酯(34mg,0.1mmol)与(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(26mg,0.12mmol)与K2CO3(0.2g,1.45mmol)混合,添加乙腈(3ml)加热至40℃搅拌4小时。反应完成后(通过TLC监测),将反应混合物分离在真空中浓缩。这样得到的粗反应混合物用二氯甲烷洗涤,然后用EtOAc洗涤,最后用MeOH(各1mL) 洗涤。最后,使用EtOAc(在温暖条件下)对反应产物进行重结晶以得到纯形式的(5-(3-(3- 溴苯基)脲基)-6-甲基吡啶-2-基)氨基甲酸叔丁酯I-14-2(34mg,81%)液相质谱 m/z=421.1[M+H]+
步骤3:1-(6-氨基-2-甲基吡啶-3-基)-3-(对甲苯基)脲
向(5-(3-(3-溴苯基)脲基)-6-甲基吡啶-2-基)氨基甲酸叔丁酯(34mg,0.08mmol)中加入 HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到1-(6-氨基-2-甲基吡啶-3-基)-3-(对甲苯基)脲A-4-2(20mg,78%) 液相质谱m/z=321.0[M+H]+
实施例13:6-氨基-N,2-二甲基-N-苯基烟酰胺A-5
其合成路线为:
步骤1:(5-溴-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-15
将5-溴-6-甲基吡啶-2-胺(37mg,0.2mmol)与二叔丁基二碳酸酐(52mg,0.24mmol)与K2CO3(69mg,0.5mmol)混合,添加四氢呋喃(5mL),室温搅拌3小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用水洗涤,用硫酸钠干燥,减压蒸馏除去溶剂,得到 (5-溴-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-15(50mg,88%)液相质谱m/z=287.0[M+H]+
步骤2:(6-甲基-5-(甲基(苯基)氨甲酰基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-17
将(5-溴-6-甲基吡啶-2-基)氨基甲酸叔丁酯(50mg,0.175mmol)与N-甲基-N-苯基甲酰胺(27mg,0.175mmol)与甲醇钠(11mg,0.2mmol),四水合二乙酸镍(25mg,0.1mmol) 混合,向其中加入1,4二氧六环(8mL),氦气保护下油浴110℃加热搅拌12h。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到(6-甲基-5-(甲基(苯基)氨甲酰基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-17(50mg,84%)液相质谱m/z=342.2[M+H]+
步骤3:6-氨基-N,2-二甲基-N-苯基烟酰胺:
向(6-甲基-5-(甲基(苯基)氨甲酰基)吡啶-2-基)氨基甲酸叔丁酯(50mg,0.147mmol)中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到6-氨基-N,2-二甲基-N-苯基烟酰胺A-5(27mg,76%)液相质谱 m/z=242.1[M+H]+
实施例14:6-甲基-N5-(四氢-2H-吡喃-4-基)吡啶-2,5-二胺A-6-1
步骤1:叔丁基(6-甲基-5-((四氢-2H-吡喃-4-基)氨基)吡啶-2-基)氨基甲酸酯Ⅰ-18-1
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与四氢-4H-吡喃-4-酮 (12mg,0.12mmol)混合,添加甲醇(2ml),室温下搅拌2小时,然后添加氰基硼氢化钠(20mg, 0.3mmol),室温下搅拌2小时。然后向混合物中添加NaOH水溶液(10mL,0.3mol/L)。所得混合物用DCM(20mL x 3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到叔丁基(6-甲基-5-((四氢-2H-吡喃-4-基)氨基)吡啶-2-基)氨基甲酸酯Ⅰ-18-1(23mg,75%)液相质谱m/z=308.2[M+H]+
步骤2:6-甲基-N5-(四氢-2H-吡喃-4-基)吡啶-2,5-二胺
向叔丁基(6-甲基-5-((四氢-2H-吡喃-4-基)氨基)吡啶-2-基)氨基甲酸酯(23mg,0.075mmol) 中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3: 7),减压蒸馏除去溶剂,得到6-甲基-N5-(四氢-2H-吡喃-4-基)吡啶-2,5-二胺A-6-1(12mg, 78%)液相质谱m/z=208.1[M+H]+
实施例15:6-甲基-N5-(吡啶-4-基甲基)吡啶-2,5-二胺A-6-2
步骤1:(6-甲基-5-((吡啶-4-基甲基)氨基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-18-2
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与异烟醛(13mg,0.12mmol)混合,添加甲醇(2ml),室温下搅拌2小时,然后添加氰基硼氢化钠(20mg,0.3mmol),室温下搅拌2小时。然后向混合物中添加NaOH水溶液(10mL,0.3mol/L)。所得混合物用DCM(20mL x 3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到(6- 甲基-5-((吡啶-4-基甲基)氨基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-18-2(24mg,76%)液相质谱 m/z=314.2[M+H]+
步骤2:6-甲基-N5-(吡啶-4-基甲基)吡啶-2,5-二胺:
向叔丁基(6-甲基-5-((四氢-2H-吡喃-4-基)氨基)吡啶-2-基)氨基甲酸酯(23mg,0.075mmol) 中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3: 7),减压蒸馏除去溶剂,得到6-甲基-N5-(四氢-2H-吡喃-4-基)吡啶-2,5-二胺A-6-2(12mg, 78%)液相质谱m/z=208.1[M+H]+
实施例16:N5-环丁基-6-甲基吡啶-2,5-二胺A-6-3
步骤1:(5-(环丁胺基)-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-18-3
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与环丁酮(8mg,0.12mmol) 混合,添加甲醇(2ml),室温下搅拌2小时,然后添加氰基硼氢化钠(20mg,0.3mmol),室温下搅拌2小时。然后向混合物中添加NaOH水溶液(10mL,0.3mol/L)。所得混合物用DCM(20mL x 3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到(5-(环丁胺基)-6- 甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-18-3(20mg,72%)液相质谱m/z=278.2[M+H]+
步骤2:N5-环丁基-6-甲基吡啶-2,5-二胺:
向(5-(环丁胺基)-6-甲基吡啶-2-基)氨基甲酸叔丁酯(20mg,0.072mmol)中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到6-甲基-N5-(四氢-2H-吡喃-4-基)吡啶-2,5-二胺A-6-3(10mg,78%)液相质谱m/z=178.1[M+H]+
实施例17:2-(6-氨基-2-甲基吡啶-3-基)异吲哚-1,3-二酮A-7
其合成线路为:
步骤1:叔丁基(5-(1,3-二氧异辛醇-2-基)-6-甲基吡啶-2-基)氨基甲酸酯Ⅰ-20
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与异苯并呋喃-1,3-二酮 (18mg,0.12mmol)混合,添加N,N-二甲基乙酰胺(2ml),室温下搅拌24小时,然后再加入二甲苯(1ml),油浴140℃搅拌48小时。完成后(通过TLC监测),通过过滤分离不溶性催化剂,用丙酮洗涤并干燥。在减压下浓缩有机层以得到所需产物,用水洗涤,并在乙醇中重结晶,粗品经硅胶柱层析(CH2Cl2/正己烷=1:1)纯化,减压蒸馏除去溶剂,得到叔丁基(5-(1,3-二氧异辛醇-2-基)-6-甲基吡啶-2-基)氨基甲酸酯Ⅰ-20(24mg,68%)液相质谱 m/z=354.1[M+H]+
步骤2:2-(6-氨基-2-甲基吡啶-3-基)异吲哚-1,3-二酮
向叔丁基(5-(1,3-二氧异辛醇-2-基)-6-甲基吡啶-2-基)氨基甲酸酯(24mg,0.068mmol) 中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3: 7),减压蒸馏除去溶剂,得到2-(6-氨基-2-甲基吡啶-3-基)异吲哚-1,3-二酮A-7(12mg,70%) 液相质谱m/z=254.1[M+H]+
实施例18:6-甲基-N5-苯基吡啶-2,5-二胺A-8
其合成线路为:
步骤1:(6-甲基-5-(苯胺基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-22
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与碘苯(24mg,0.12mmol), (N,N-联吡啶基咪唑亚基)二溴化铜(10mg,0.023mmol),碳酸铯(100mg,0.3mmol)混合,添加1,4-二氧六环(5ml),油浴170℃搅拌12小时。然后向混合物中添加NaOH水溶液(10mL,0.3mol/L)。所得混合物用DCM(20mL x 3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到(6-(甲基-5-(苯胺基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-22(25mg,84%)液相质谱m/z=300.2[M+H]+
步骤2:6-甲基-N5-苯基吡啶-2,5-二胺:
向(6-(甲基-5-(苯胺基)吡啶-2-基)氨基甲酸叔丁酯(25mg,0.084mmol)中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到6-甲基-N5-苯基吡啶-2,5-二胺A-8(12mg,72%)液相质谱m/z=200.1[M+H]+
实施例19:(E)-6-甲基-5-苯乙烯基吡啶-2-胺A-9
其合成线路为:
步骤1:叔丁基(E)-(6-甲基-5-苯乙烯基吡啶-2-基)氨基甲酸酯Ⅰ-24
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与苯乙烯(13mg,0.12mmol),双(二亚苄基丙酮)-钯(0)(5mg,0.0087mmol)混合,添加亚硝基叔丁酯(0.5ml),氯乙酸(0.5ml),乙酸(3ml)油浴50℃搅拌2小时。然后向混合物中添加NaOH水溶液(10mL,0.3mol/L)。所得混合物用DCM(20mL x 3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到叔丁基(E)-(6-甲基-5-苯乙烯基吡啶-2-基)氨基甲酸酯Ⅰ-24(22mg,71%)液相质谱m/z=311.2[M+H]+
步骤2:(E)-6-甲基-5-苯乙烯基吡啶-2-胺:
向叔丁基(E)-(6-甲基-5-苯乙烯基吡啶-2-基)氨基甲酸酯(22mg,0.071mmol)中加入HCl 的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到(E)-6-甲基-5-苯乙烯基吡啶-2-胺A-9(13mg,88%)液相质谱 m/z=211.1[M+H]+
实施例20:N-(6-氨基-2-甲基吡啶-3-基)噻吩-2-磺酰胺A-10
其合成线路为:
步骤1:(6-甲基-5-(噻吩-2-磺胺基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-26
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(22mg,0.1mmol)与噻吩-2-磺酰氯(22mg, 0.12mmol)混合,添加三乙胺(0.5ml),二氯甲烷(3ml),氮气保护下室温搅拌24小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化,减压蒸馏除去溶剂,得到(6-甲基-5-(噻吩-2-磺胺基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-26(19mg,52%)液相质谱m/z=370.1[M+H]+
步骤2:N-(6-氨基-2-甲基吡啶-3-基)噻吩-2-磺酰胺
向(6-甲基-5-(噻吩-2-磺胺基)吡啶-2-基)氨基甲酸叔丁酯(19mg,0.052mmol)中加入HCl 的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7),减压蒸馏除去溶剂,得到N-(6-氨基-2-甲基吡啶-3-基)噻吩-2-磺酰胺A-10(10mg,72%)液相质谱 m/z=270.0[M+H]+
实施例21:N-(2-((6-氨基-2-甲基吡啶-3-基)氨基)乙基)甲磺酰胺A-11
其合成线路为:
步骤1:(5-((2-氨基乙基)氨基)-6-甲基吡啶-2-基)氨基甲酸叔丁酯Ⅰ-28
将(5-氨基-6-甲基吡啶-2-基)氨基甲酸叔丁酯(44mg,0.2mmol)与2-溴乙烷-1-胺(29mg, 0.24mmol)混合,加入水(5ml),油浴95℃搅拌18小时。反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。混合物在硅胶(CH2Cl2甲醇-氨水)上通过快速色谱纯化得到所需产物。减压蒸馏除去溶剂,得到(5-((2-氨基乙基)氨基)-6-甲基吡啶-2-基) 氨基甲酸叔丁酯Ⅰ-28(38mg,72%)液相质谱m/z=267..2[M+H]+
步骤2:(6-甲基-5-((2-(甲基磺胺基)乙基)氨基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-30
将(5-((2-氨基乙基)氨基)-6-甲基吡啶-2-基)氨基甲酸叔丁酯(38mg,0.144mmol)与甲磺酰氯(28mg,0.16mmol)混合,加入二氯甲烷(5ml),冰水浴搅拌24小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化,减压蒸馏除去溶剂,得到(6-甲基-5-((2-(甲基磺胺基)乙基)氨基)吡啶-2-基)氨基甲酸叔丁酯Ⅰ-30(20mg,40%),液相质谱m/z=255.1[M+H]+
步骤3:N-(2-((6-氨基-2-甲基吡啶-3-基)氨基)乙基)甲磺酰胺
向(6-甲基-5-((2-(甲基磺胺基)乙基)氨基)吡啶-2-基)氨基甲酸叔丁酯(20mg,0.057mmol) 中加入HCl的二氧六环溶液(5%,5mL),70℃加热搅拌3h,向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3: 7),减压蒸馏除去溶剂,得到N-(2-((6-氨基-2-甲基吡啶-3-基)氨基)乙基)甲磺酰胺A-11(11mg, 78%)液相质谱m/z=245.1[M+H]+
实施例22:3-((1H-苯并[d]咪唑-6-基)氧甲基)苯甲腈B-1-1
步骤:将1H-苯并[d]咪唑-6-醇II-3(9mg,0.07mmol)与3-(溴甲基)苯甲腈(20mg,0.1mmol)与K2CO3(138mg,1mmol)混合,添加乙腈(2ml),并将混合物加热至40℃搅拌10分钟。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:甲醇=40:1)纯化得到3-((1H-苯并[d]咪唑-6-基)氧甲基)苯甲腈B-1-1(10mg,57%)液相质谱m/z=249.3[m+H]+
实施例23:6-苯氧基-1H-苯并[d]咪唑B-1-2
步骤:将1H-苯并[d]咪唑-6-醇II-3(9mg,0.07mmol)与(2-溴乙基)苯(22mg,0.12mmol)与K2CO3(138mg,1mmol)混合,添加乙腈(2ml),并将混合物加热至40℃搅拌10分钟。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:甲醇=40:1)纯化得到6-苯氧基-1H-苯并[d]咪唑B-1-2(12mg,70%)液相质谱m/z=238.1[m+H]+
实施例24:2-(1H-苯并[d]咪唑-6-基)异吲哚-1-酮B-2
其合成路线:
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与2-甲酰基苯甲酸(18mg,0.12mmol) 混合,添加甲酸(0.2ml),三乙胺(1ml),乙醇(1ml),将混合物加热至80℃搅拌60分钟。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:乙酸乙酯=20:1)纯化得到2-(1H-苯并[d]咪唑-6-基)异吲哚-1-酮B-2 (13mg,54%)液相质谱m/z=249.1[m+H]+
实施例25:N-(1H-苯并[d]咪唑-6-基)噻吩-3-甲酰胺B-3-1
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与噻吩-2-羧酸(15mg,0.12mmol)与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加 N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到N-(1H-苯并[d]咪唑-6-基)噻吩-3-甲酰胺B-3-1(9mg,37%)液相质谱m/z=243.1[m+H]+
实施例26:(E)-N-(1H-苯并[d]咪唑-6-基)-2-甲基-2-烯酰胺B-3-2
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与(E)-2-甲基-2-烯酸(12mg,0.12mmol)与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析 (乙酸乙酯:己烷=3:7)纯化得到(E)-N-(1H-苯并[d]咪唑-6-基)-2-甲基-2-烯酰胺B-3-2(10 mg,46%)液相质谱m/z=215.1[m+H]+
实施例27:N-(1H-苯并[d]咪唑-6-基)-2,3-二氢苯并呋喃-2-甲酰胺B-3-3
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与苯并呋喃-2-羧酸(19mg,0.12mmol) 与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加 N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到N-(1H-苯并[d]咪唑-6-基)-2,3-二氢苯并呋喃-2-甲酰胺B-3-3(12 mg,41%)液相质谱m/z=279.1[m+H]+
实施例28:N-(1H-苯并[d]咪唑-6-基)-3,4-二氯苯甲酰胺B-3-4
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与3,4-二氯苯甲酸(23mg,0.12mmol) 与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加 N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到N-(1H-苯并[d]咪唑-6-基)-3,4-二氯苯甲酰胺B-3-4(12mg,39%) 液相质谱m/z=305.0[m+H]+
实施例29:N-(1H-苯并[d]咪唑-6-基)苯并[b]噻吩-2-甲酰胺B-3-5
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与苯并噻吩-2-羧酸(21mg,0.12mmol) 与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加 N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到N-(1H-苯并[d]咪唑-6-基)苯并[b]噻吩-2-甲酰胺B-3-5(13mg, 43%)液相质谱m/z=293.1[m+H]+
实施例30:N-(1H-苯并[d]咪唑-6-基)-2-苯乙酰胺B-3-6
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与2-苯乙酸(16mg,0.12mmol) 与2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加N,N-二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化得到N-(1H-苯并[d]咪唑-6-基)-2-苯乙酰胺B-3-6(11mg,43%)液相质谱m/z=251.11[m+H]+
实施例31:1-(1H-苯并[d]咪唑-6-基)-3-(对甲苯基)脲B-4-1
步骤1:对硝基苯基对甲苯氨基碳酸酯II-9-1
将对甲苯胺(21mg,0.2mmol)与4-硝基苯基羰酰氯(48mg,0.24mmol)混合,添加三乙醇胺(0.2ml),二氯甲烷(1ml),四氢呋喃(2ml)室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:己烷=5:1)纯化得到对硝基苯基对甲苯氨基碳酸酯II-9-1(42mg,77%)液相质谱m/z=273.1[m+H]+
步骤2:1-(1H-苯并[d]咪唑-6-基)-3-(对甲苯基)脲
将对硝基苯基对甲苯氨基甲酸酯(27mg,0.1mmol)与1H-苯并[d]咪唑-6-胺(16mg,0.12mmol)与K2CO3(0.2g,1.45mmol)混合,添加乙腈(3ml)加热至40℃搅拌4小时。反应完成后(通过TLC监测),将反应混合物分离在真空中浓缩。这样得到的粗反应混合物用二氯甲烷洗涤,然后用EtOAc洗涤,最后用MeOH(各1mL)洗涤。最后,使用EtOAc (在温暖条件下)对反应产物进行重结晶以得到纯形式的1-(1H-苯并[d]咪唑-6-基)-3-(对甲苯基)脲B-4-1(20mg,75%)液相质谱m/z=266.1[m+H]+
实施例32:1-(1H-苯并[d]咪唑-6-基)-3-(3-溴苯基)脲B-4-2
步骤1:4-硝基苯基(3-溴苯基)氨基碳酸酯II-9-2
将3-溴苯胺(34mg,0.2mmol)与4-硝基苯基羰酰氯(48mg,0.24mmol)混合,添加三乙醇胺(0.2ml),二氯甲烷(1ml),四氢呋喃(2ml)室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(二氯甲烷:己烷=5:1)纯化得到4-硝基苯基(3-溴苯基)氨基碳酸酯II-9-2(46mg,68%)液相质谱m/z=338.1[m+H]+
步骤2:1-(1H-苯并[d]咪唑-6-基)-3-(3-溴苯基)脲
将4-硝基苯基(3-溴苯基)氨基碳酸酯(34mg,0.1mmol)与1H-苯并[d]咪唑-6-胺(16mg, 0.12mmol)与K2CO3(0.2g,1.45mmol)混合,添加乙腈(3ml)加热至40℃搅拌4小时。反应完成后(通过TLC监测),将反应混合物分离在真空中浓缩。这样得到的粗反应混合物用二氯甲烷洗涤,然后用EtOAc洗涤,最后用MeOH(各1mL)洗涤。最后,使用EtOAc (在温暖条件下)对反应产物进行重结晶以得到纯形式的1-(1H-苯并[d]咪唑-6-基)-3-(3-溴苯基)脲B-4-2(22mg,68%)液相质谱m/z=330.0[m+H]+
实施例33:N-甲基-N-苯基-1H-苯并[d]咪唑-6-甲酰胺B-5
其合成路线为:
步骤1:6-硝基-1H-苯并[d]咪唑II-10
向发烟硫酸(500μL)中的H2O2(240mg,2.2mmol)溶液中逐滴添加1h-苯并[d]咪唑-6-胺(40mg,0.3mmol)的浓硫酸(100μL)溶液,将反应温度保持在0℃。在10-25℃下搅拌3h后,通过在0-5℃下添加40%NaOH水溶液使反应混合物达到pH=11-12。所得混合物用乙酸乙酯萃取。用饱和氯化钠水溶液洗涤合并的有机层,在Na2SO4上干燥并过滤。减压蒸馏除去溶剂,得到所需6-硝基-1H-苯并[d]咪唑IⅠ-10(35mg,72%)LC-mS m/z=163.0[m+H]+
步骤2:1H-苯并[d]咪唑-6-羧酸II-11
将6-硝基-1H-苯并[d]咪唑(39mg,0.24mmol)与KCN(195mg,3mmol)混合添加 1-丁基咪唑四氟硼酸盐(3mg,0.014mmol),EtOH(2ml),水(2ml)加热至80℃搅拌 19小时。然后加入10ml水,用CH2Cl2(3×5ml)和乙醚(3×10ml)萃取混合物。用盐酸酸化至pH1-2,用乙醚(3×10ml)萃取。加入硫酸镁(3g)和活性碳(1g)并搅拌5h。过滤掉固体,蒸发滤液,并将残余物从相应溶剂中结晶,得到所需1H-苯并[d]咪唑-6-羧酸II-11 (14mg,40%)LC-mS m/z=162.0[m+H]+
步骤3:N-甲基-N-苯基-1H-苯并[d]咪唑-6-甲酰胺
将1H-苯并[d]咪唑-6-羧酸(16mg,0.1mmol)与N-甲基苯胺(13mg,0.12mmol)与 2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(38mg,0.1mmol)混合,添加N,N- 二异丙基乙胺(0.2ml),N,N-二甲基甲酰胺(2ml),室温下搅拌18小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化,减压蒸馏除去溶剂,得到N-甲基-N-苯基-1H-苯并[d]咪唑-6-甲酰胺B-5 (16mg,65%)液相质谱m/z=251.1[m+H]+
实施例34:N-(四氢-2H-吡喃-4-基)-1H-苯并[d]咪唑-6-胺B-6-1
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与四氢-4H-吡喃-4-酮(12mg,0.12mmol)混合,添加甲醇(2ml),室温下搅拌2小时,然后添加氰基硼氢化钠(20mg,0.3mmol),室温下搅拌2小时。然后向混合物中添加NaOH水溶液(10mL,0.3mol/L)。所得混合物用DCM(20mLx3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到N-(四氢-2H- 吡喃-4-基)-1H-苯并[d]咪唑-6-胺B-6-1(16mg,75%)液相质谱m/z=217.1[m+H]+
实施例35:N-(吡啶-4-甲基)-1H-苯并[d]咪唑-6-胺B-6-2
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与异烟醛(13mg,0.12mmol)混合,添加甲醇(2ml),室温下搅拌2小时,然后添加氰基硼氢化钠(20mg,0.3mmol),室温下搅拌2小时。然后向混合物中添加NaOH水溶液(10mL,0.3mol/L)。所得混合物用 DCM(20mLx3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到N-(吡啶-4-甲基)-1H- 苯并[d]咪唑-6-胺B-6-2(14mg,64%)液相质谱m/z=224.1[m+H]+
实施例36:正环丁基-1H-苯并[d]咪唑-6-胺B-6-3
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与环丁酮(8mg,0.12mmol)混合,添加甲醇(2ml),室温下搅拌2小时,然后添加氰基硼氢化钠(20mg,0.3mmol),室温下搅拌2小时。然后向混合物中添加NaOH水溶液(10mL,0.3mol/L)。所得混合物用DC m(20mLx3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到正环丁基-1H-苯并 [d]咪唑-6-胺B-6-3(13mg,72%)液相质谱m/z=187.1[m+H]+
实施例37:2-(1H-苯并[d]咪唑-6-基)异吲哚啉-1,3-二酮B-7
其合成路线:
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与异苯并呋喃-1,3-二酮(18mg,0.12 mmol)混合,添加N,N-二甲基乙酰胺(2ml),室温下搅拌24小时,然后再加入二甲苯(1ml),油浴140℃搅拌48小时。完成后(通过TLC监测),通过过滤分离不溶性催化剂,用丙酮洗涤并干燥。在减压下浓缩有机层以得到所需产物,用水洗涤,并在乙醇中重结晶,粗品经硅胶柱层析(CH2Cl2/正己烷=1:1)纯化,减压蒸馏除去溶剂,得到2-(1H-苯并[d]咪唑 -6-基)异吲哚啉-1,3-二酮B-7(18mg,68%)液相质谱m/z=263.1[m+H]+
实施例38:N-苯基-1H-苯并[d]咪唑-6-胺B-8
其合成路线:
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与碘苯(24mg,0.12mmol),(N,N-联吡啶基咪唑亚基)二溴化铜(10mg,0.023mmol),碳酸铯(100mg,0.3mmol)混合,添加1,4-二氧六环(5ml),油浴170℃搅拌12小时。然后向混合物中添加NaOH水溶液(10 mL,0.3mol/L)。所得混合物用DCM(20mLx3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到N-苯基-1H-苯并[d]咪唑-6-胺B-8(17mg,82%)液相质谱m/z=209.1[m+H]+
实施例39:(E)-6-苯乙烯基-1H-苯并[d]咪唑B-9
其合成路线:
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与苯乙烯(13mg,0.12mmol),双(二亚苄基丙酮)-钯(0)(5mg,0.0087mmol)混合,添加亚硝基叔丁酯(0.5ml),氯乙酸(0.5ml),乙酸(3ml)油浴50℃搅拌2小时。然后向混合物中添加NaOH水溶液(10mL,0.3 mol/L)。所得混合物用DCM(20mLx3)萃取。合并的有机相在无水Na2SO4上干燥,过滤并在真空中浓缩。粗品经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,减压蒸馏除去溶剂,得到(E)-6-苯乙烯基-1H-苯并[d]咪唑B-9(13mg,61%)液相质谱m/z=220.1[m+H]+
实施例40:N-(1H-苯并[d]咪唑-6-基)噻吩-2-磺酰胺B-10
其合成线路:
步骤:将1H-苯并[d]咪唑-6-胺(13mg,0.1mmol)与噻吩-2-磺酰氯(22mg,0.12mmol) 混合,添加三乙胺(0.5ml),二氯甲烷(3ml),氮气保护下室温搅拌24小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化,减压蒸馏除去溶剂,得到N-(1H-苯并[d]咪唑-6-基)噻吩-2-磺酰胺 B-10(13mg,45%)液相质谱m/z=279.0[m+H]+
实施例41:N-(2-(1h苯并[d]咪唑-6-基)氨基乙基)甲基磺酰胺B-11
其合成线路:
步骤1:N1-(1H-苯并[d]咪唑-6-基)乙烷-1,2-二胺ⅠI-19
将1H-苯并[d]咪唑-6-胺(27mg,0.2mmol)与2-溴乙烷-1-胺(29mg,0.24mmol)混合,加入水(5ml),油浴95℃搅拌18小时。反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。混合物在硅胶(CH2Cl2甲醇-氨水)上通过快速色谱纯化得到所需产物。减压蒸馏除去溶剂,得到N1-(1H-苯并[d]咪唑-6-基)乙烷-1,2-二胺ⅠI-19(22mg,61%)液相质谱m/z=176.1[m+H]+
步骤2:N-(2-(1h苯并[d]咪唑-6-基)氨基乙基)甲基磺酰胺
将N1-(1H-苯并[d]咪唑-6-基)乙烷-1,2-二胺(23mg,0.13mmol)与甲磺酰氯(28mg, 0.16mmol)混合,加入二氯甲烷(5ml),冰水浴搅拌24小时。向反应混合物中加入乙酸乙酯和水,分离有机层,用硫酸钠干燥,减压浓缩。残渣经硅胶柱层析(乙酸乙酯:己烷=3:7)纯化,减压蒸馏除去溶剂,得到N-(2-(1H苯并[d]咪唑-6-基)氨基乙基)甲基磺酰胺B-11(11mg,32%),液相质谱m/z=254.1[m+H]+
小分子结合能预测:
利用AutoDock Vina和LeDock软件分别对实施例1-21中的氨基吡啶衍生物分子、实施例22-41中的苯并咪唑衍生物分子与OCT4靶标蛋白进行分子对接,分别生产10个对接构象。计算每一氨基吡啶衍生物分子、每一苯并咪唑衍生物分子与OCT4靶标蛋白最优对接结果的结合能与配体效率,综合对接结果进行氨基吡啶衍生物分子、苯并咪唑衍生物分子筛选,具体对接结果分别如表1、表2所示:表第二、三列分别由autodock vina和LeDock分子对接软件计算获得的结合自由能(binding energy),其值越负,小分子配体与靶蛋白结合能力越强。表第四列代表由LeDock计算产生的配体效率(ligand efficiency),其绝对值越大表示小分子活性具有更强的潜能。在本发明中根据两个软件的独立算法,预测出本发明涉及化合物的结合能水平,预测值显示本发明中的化合物其结合能均远大于本发明根据靶点特征设定的阈值3。
表1.本发明所用氨基吡啶衍生物分子与靶标蛋白的结合预测
表2.本发明所用苯并咪唑衍生物分子与靶向序列的结合能预测
小分子引起的转录表达差异验证:
本发明的目的是使用高选择性活化剂达到启动目标基因的作用,此类活化剂的重要功能为启动Oct4的表达,从而增加Oct4对下游基因的表达丰度。因此,在验证本发明的小分子功能时,除了验证Oct4基因自身增加幅度外,Oct4基因的下游基因Nanog的表达增加也是本发明中化合物的一个功能验证的指标。
在T25培养人间充质细胞,按照4x105接种细胞,使用无血清杜氏改良伊格尔培养基 (DMEM-F12培养基),其中分别添加50nM上述氨基吡啶衍生物小分子及苯并咪唑衍生物小分子进行培养,培养条件为37℃,5%二氧化碳。于第5天分别使用RNeasy Mini or MicroKit(QIAGEN)进行总RNA抽提,1mg RNA用SuperScript III First-Strand SynthesisSystem (Invitrogen)合成cDNA。用SYBR Premix Ex Taq(TaKaRa)和Thermal Cycler DiceReal Time System(TaKaRa)来进行Quantitative PCR的标记和反应,beta-Actin用来作为内参。所有数据用delta-Ct method进行分析。每组试验使用三组重复进行试验,并进行方差统计。用于鉴定不同细胞标志物的编码基因的引物序列如表3所示。结果如图1及图2所示,与不使用小分子的对照组相比,以上氨基吡啶衍生物小分子及苯并咪唑衍生物小分子对OCT4 的基础表达及其下游基因Nanog的表达均增加显著。
表3.化合物效应基因QPCR引物序列
小分子引起的早期细胞多能性验证:
Rex1基因在未分化的胚胎干细胞中高度表达,在多能干细胞的体外培养中最接近体内胚胎干细胞及植入前囊胚天然状态(Boroviak,T et al.,Nat.Cell Biol.2014.16,516–528; Kalkan,T et al.,Development.2017,144,1221–1234)。Rex1基因的表达显示了细胞正处于类似胚胎干细胞活着植入前囊胚的天然多能性状态。因此,本发明将Rex1的表达作为小分子功能的终端检测指标。
在T25培养人间充质细胞,按照4x105接种细胞,使用无血清杜氏改良伊格尔培养基 (DMEM-F12培养基),其中分别添加50nM上述氨基吡啶衍生物小分子及苯并咪唑衍生物小分子进行培养,培养条件为37℃,5%二氧化碳。于第5天进行免疫荧光染色鉴定:采用4%多聚甲醛室温固定细胞40分钟,用DPBS缓冲液清洗两遍;然后用0.1%Triton X-100透化处理5分钟,用DPBS缓冲液清洗两遍;然后用含10%马血清和0.1%Triton X-100的DPBS缓冲液将细胞4℃孵育过夜;然后加入2%马血清和0.1%Triton X-100的DPBS缓冲液1:200稀释的抗Rex1一抗(Abcam,ab28141),37℃孵育2小时,用DPBS缓冲液清洗三遍后,加入2%马血清和0.1%Triton X-100的DPBS缓冲液1:1000稀释的羊抗兔IgG(H+L),Alexa Fluor488(Invitrogen A10037)拍照。如图3所示,本发明中化学小分子可以促进间充质细胞表达Rex1基因,并让间充质细胞形成多能干细胞克隆样细胞团。
序列表
<110> 武汉睿健医药科技有限公司
<120> OCT4高选择性活化剂
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
ccatgcattc aaactgaggt 20
<210> 2
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
cctttgtgtt cccaattcct t 21
<210> 3
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
acctcagcta caaacaggtg aa 22
<210> 4
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
aaaggctggg gtaggtaggt 20
<210> 5
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
ggccgaggac tttgattgca ca 22
<210> 6
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
gggcacgaag gctcatcatt caa 23
Claims (11)
1.式(II)结构的化合物:
其中:
m1和m2分别为0或1;
A2是C1-C6亚烷基、C2-C6亚烯基、-O(CH2)q-、-NR1-、-SO2-、-(CH2)VNHS(O)2-或键,其中,q为1或2或3或4,V为0或1或2,R1选自H或C1-C4烷基;
及其药物上可接受的盐、溶剂化物、活性代谢物、多晶型物、酯、光学异构体、前药或其组合。
2.根据权利要求1所述的化合物,其中:
A2是-CH2-、-CH=CH-、-C(CH3)=CH-、-O(CH2)-、-O(CH2)2-、-NH-、-N(CH3)-、-SO2-、-NHS(O)2-、-(CH2)2NHS(O)2-或键。
9.一种药物组合物,其包含权利要求1至8中任意一项的化合物或及其药物上可接受的盐、溶剂化物、活性代谢物、多晶型物、酯、光学异构体、前药或其组合,以及至少一种药学上可接受的载体或赋形剂。
10.权利要求1至8中任意一项的所述的化合物和/或其药物上可接受的盐、溶剂化物、活性代谢物、多晶型物、酯、光学异构体、前药或其组合在制备诱导多能干细胞的OCT4高选择性活化剂的药物中的用途。
11.根据权利要求10所述的用途,OCT4高选择性活化剂诱导多能干细胞治疗的疾病包括癌症、心脏病、中风、糖尿病、肥胖、阿尔茨海默氏病、帕金森氏病、肌萎缩侧索硬化、心肌梗塞、肌营养不良、CMT-1A、脊髓损伤、外伤性脑损伤、缺牙、伤口愈合、骨髓移植、骨关节炎、类风湿性关节炎、脱发、失明、耳聋、克罗恩氏病和遗传疾病及其他相似疾病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110686581.9A CN115572256A (zh) | 2021-06-21 | 2021-06-21 | Oct4高选择性活化剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110686581.9A CN115572256A (zh) | 2021-06-21 | 2021-06-21 | Oct4高选择性活化剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115572256A true CN115572256A (zh) | 2023-01-06 |
Family
ID=84579543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110686581.9A Pending CN115572256A (zh) | 2021-06-21 | 2021-06-21 | Oct4高选择性活化剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115572256A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011131748A2 (en) * | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
US20130317004A1 (en) * | 2010-11-11 | 2013-11-28 | Bayer Intellectual Property Gmbh | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US20170130198A1 (en) * | 2014-06-20 | 2017-05-11 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial inhibitors for use in culturing pluripotent stem cells |
US20200062719A1 (en) * | 2018-08-14 | 2020-02-27 | University Of Heidelberg | Application of Imidazopyridine Derivatives in Regenerative Medicine |
-
2021
- 2021-06-21 CN CN202110686581.9A patent/CN115572256A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011131748A2 (en) * | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
US20130317004A1 (en) * | 2010-11-11 | 2013-11-28 | Bayer Intellectual Property Gmbh | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US20170130198A1 (en) * | 2014-06-20 | 2017-05-11 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial inhibitors for use in culturing pluripotent stem cells |
US20200062719A1 (en) * | 2018-08-14 | 2020-02-27 | University Of Heidelberg | Application of Imidazopyridine Derivatives in Regenerative Medicine |
Non-Patent Citations (1)
Title |
---|
REGISTRY数据库, STNEXT, 19 May 2016 (2016-05-19), pages 1 - 22 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2695521C2 (ru) | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение | |
US9126984B2 (en) | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | |
US11440893B2 (en) | Prodrugs of riluzole and their method of use | |
EP2876105A1 (en) | 1-(cycloalkyl-carbonyl)proline derivative | |
JP2017514830A (ja) | リジン特異的なデメチラーゼ−1の阻害剤 | |
WO2014137723A1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
US11197864B2 (en) | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | |
JP2021509683A (ja) | ピリジルイミダゾベンゾジアゼピンプロピオン酸エステル化合物およびその合成と使用 | |
JP6619796B2 (ja) | Mif阻害剤 | |
US20220048889A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
BRPI0509667B1 (pt) | composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto | |
CN115572256A (zh) | Oct4高选择性活化剂 | |
CN115572285A (zh) | Oct4高选择性活化剂 | |
EP4361131A1 (en) | Oct4 high-selectivity activator | |
KR20150079616A (ko) | 암 치료를 위한 베타-하이드록실라제의 억제제 | |
JP2021519825A (ja) | 輸送体の調節薬としての二環式エノンカルボキシラートとその使用 | |
JPWO2018016458A1 (ja) | ピペラジン誘導体 | |
EP4138824A1 (en) | Lox enzyme inhibiting methods and compositions | |
CN116283964A (zh) | 一种吡咯并吡啶衍生物及其药物组合物与应用 | |
TW201141476A (en) | Novel indole derivative | |
CN115948325A (zh) | 一种诱导间质细胞向上皮细胞转化及重编程的诱导剂 | |
EP3447045B9 (en) | 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria | |
ES2965684T3 (es) | Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular | |
WO2019196780A1 (zh) | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 | |
TW202235408A (zh) | 化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |